Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL 

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL 

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Electric field device placed on the scalp, along with immunotherapy and chemotherapy may help patients with glioblastoma live longer, particularly those with large, inoperable tumors.

Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer?

 team as an assistant editor in 2025 after previously working on the 

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Health Canada Approves Quizartinib Plus Chemotherapy for Newly Diagnosed FLT3-ITD+ AML

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

The OncLive Insider app is live!

CME Opportunities

Specialty

Onclive® Publications

Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Targeting BCL-2 in Hematologic Malignancies

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

BCL-2: Mechanisms and Prevalence

Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies

Latest Conference Coverage